

# References

## Chapter 32

- 1 Sketris I, Ingram EL, Lummis H. Optimal Prescribing and Medication Use in Canada: Challenges and Opportunities. Last accessed: [http://healthcouncilcanada.ca/tree/2.37.1-Appendices\\_Optimizing\\_PrescribingBehaviours.pdf](http://healthcouncilcanada.ca/tree/2.37.1-Appendices_Optimizing_PrescribingBehaviours.pdf) (18 November 2015).
- 2 Denig P, Haaijer-Ruskamp FM, Zijsling DH. How physicians choose drugs. *Social Science & Medicine*. 1988;**27**(12):1381–6.
- 3 Haaijer-Ruskamp FM, Hemminki E. *The Social Aspects of Drug Use. Dukes MNG. Drug Utilization Studies: Methods and Uses*. Finland, WHO Regional Publications, 1993.
- 4 Wirtz V, Cribb A, Barber N. Patient-doctor decision-making about treatment within the consultation – a critical analysis of models. *Social Science & Medicine*. 2006;**62**(1):116–24.
- 5 De Vries TPGM, Henning RH, Hogerzeil HV, Fresle DA. *Guide to Good Prescribing*. Geneva, World Health Organization, 1995. Available from: <http://apps.who.int/medicinedocs/pdf/whozip23e/whozip23e.pdf> (last accessed 18 November 2015).
- 6 Maxwell S, Walley T. Teaching safe and effective prescribing in UK medical schools: a core curriculum for tomorrow's doctors. *British Journal of Clinical Pharmacology*. 2003;**55**:496–503.
- 7 Sjoqvist F, Orme M. Clinical pharmacology in research, teaching and health care. *Basic & Clinical Pharmacology & Toxicology*. 2010;**107**:531–59.
- 8 World Health Organization. Medicines: Country Situational Analysis. Available from: [http://www.searo.who.int/entity/medicines/country\\_situational\\_analysis/en/](http://www.searo.who.int/entity/medicines/country_situational_analysis/en/) (last accessed 18 November 2015).
- 9 Latter S, Blenkinsopp A, Smith A, Chapman S, Tinelli M, Gerard K, Dorer G. Evaluation of nurse and pharmacist independent prescribing. University of Southampton & Keele University. Available from: [http://eprints.soton.ac.uk/184777/3/ENPIP\\_fullreport.pdf](http://eprints.soton.ac.uk/184777/3/ENPIP_fullreport.pdf) (last accessed 18 November 2015).
- 10 Kroezen M, van Dijk L, Groenewegen PP, Francke AL. Nurse prescribing of medicines in Western European and Anglo-Saxon countries: a systematic review of the literature. *BMC Health Services Research*. 2011;**11**:127.
- 11 Bhanbhro S, Drennan VM, Grant R, Harris R. Assessing the contribution of prescribing in primary care by nurses and professionals allied to medicine: a systematic review of literature. *BMC Health Services Research*. 2011;**11**:330.
- 12 Holloway KA, Ivanovska I, Wagner AK, Vialle-Valentin C, Ross-Degnan R. Have we improved use of medicines in developing countries and do we know how to? Two decades of evidence. *Tropical Medicine and International Health*. 2013;**18**(6):656–64.
- 13 Holloway KA, Ivanovska I, Wagner AK, Vialle-Valentin C, Ross-Degnan R. Prescribing for acute childhood infections in developing and transitional countries, 1990–2009. *Paediatrics and International Child Health*. 2015;**35**(1):5–13.
- 14 Denig P, Haaijer-Ruskamp FM. Therapeutic decision making of physicians. *Pharmaceutisch Weekblad*. 1992;**14**:9–15.
- 15 Bissessur SW, Geijteman EC, Al-Dulaimy M, Teunissen PW, Richir MC, Arnold AE, de Vries TP. Therapeutic reasoning: from hiatus to hypothetical model. *Journal of Evaluation in Clinical Practice*. 2009;**15**:985–9.
- 16 Figueras A. The use of drugs is not as rational as we believe... but it can't be! The emotional roots of prescribing. *European Journal of Clinical Pharmacology*. 2011;**67**:433–5.
- 17 Hafler JP, Ownby AR, Thompson BM, Fasser CE, Grigsby K, Haidet P, et al. Decoding the learning environment of medical education: a hidden curric-

- ulum perspective for faculty development. *Academic Medicine*. 2011;**86**:440–4.
- 18 National Institute for Health and Care Excellence. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. NICE Guidelines CG67. Available from: <https://www.nice.org.uk/guidance/cg67> (18 November 2015).
- 19 Sackett D, Rosenberg WMC, Gray JAM, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. *British Medical Journal*. 1996;**312**:71.
- 20 Carthy P, Harvey I, Brawn R, Watkins C. A study of factors associated with cost and variation in prescribing among GPs. *Family Practice*. 2000;**17**:36–41.
- 21 Eiermann B, Bastholm-Rahmner P, Korkmaz S, Lilja B, Veg A, Wettermark B, Gustafsson LL. Knowledge databases for clinical decision support in drug prescribing – development, quality assurance, management, integration, implementation and evaluation of clinical value. In: Jao CS, ed. *Decision Support Systems*. Vienna, InTech, 2010.
- 22 Schedlbauer A, Prasad V, Mulvaney C, Phansalkar S, Stanton W, Bates DW, Avery AJ. What evidence supports the use of computerized alerts and prompts to improve clinicians' prescribing behaviour? *Journal of the American Medical Association*. 2009;**16**(4):531–8.
- 23 Avery A, Barber N, Ghaleb M, Franklin BD, Armstrong S, Crowe S, et al. Investigating the Prevalence and Causes of Prescribing Errors in General Practice: The PRACtICE Study. Available from: <http://docplayer.net/406579-Investigating-the-prevalence-and-causes-of-prescribing-errors-in-general-practice-the-practice-study-a-report-for-the-gmc.html> (18 November 2015).
- 24 Black AD, Car J, Pagilari C, Anandan C, Cresswell Kokun T, et al. The impact of ehealth on the quality and safety of health care: a systematic overview. *PLoS Medicine*. 2011;**8**(1):e1000387.
- 25 De Smet PAGM, Dautzenberg M. Repeat prescribing. *Drugs*. 2004;**64**:1779–800.
- 26 Petty DR, Zermansky AG, Alldred DP. The scale of repeat prescribing-time for an update. *BMC Health Services Research*. 2014;**14**:76.
- 27 Zermansky AG. Who controls repeat prescribing? *British Journal of General Practice*. 1996;**46**:643–7.
- 28 Coleman R, Gill G, Wilkinson D. Noncommunicable disease management in resource-poor settings: a primary care model from rural South Africa. *Bulletin of the World Health Organization*. 1998;**76**(6):633.
- 29 Lewis PJ, Tully MP. The discomfort caused by patient pressure on the prescribing decisions of hospital prescribers. *Research in Social & Administrative Pharmacy*. 2011;**7**:4–15.
- 30 Huttner, B, Goossens H, Verheij T, Harbarth S. Characteristics and outcomes of public campaigns aimed at improving the use of antibiotics in outpatients in high-income countries. *Lancet Infectious Diseases*. 2010;**10**:17–31.
- 31 Pound P, Britten N, Morgan M, Yardley, L, Pope C, Daker-White G, Campbell R. Resisting medicines: a synthesis of qualitative studies of medicine taking. *Social Science & Medicine*. 2005;**61**(1):133–55.
- 32 Britten N, Stevenson FA, Barry CA, Barber N, Bradley CP. Misunderstandings in prescribing decisions in general practice: qualitative study. *British Medical Journal*. 2000;**320**:484–8.
- 33 Hadiyono JEP, Suryawati S, Danu SS, Sunartono, Santoso B. Interactional group discussion: results of a controlled trial using a behavioural intervention to reduce the use of injections in public health facilities. *Social Science and Medicine*. 1996;**42**(8):1177–83.
- 34 Bond C, Blenkinsopp A, Raynor D. Prescribing and partnership with patients. *British Journal of Clinical Pharmacology*. 2012;**74**:581–8.
- 35 National Voices. *Supporting Shared Decision-Making: Summarising Evidence from Systematic Reviews*. London, The Evidence Centre for National Voices, 2014.
- 36 Teixeira Rodrigues A, Roque F, Falcão A, Figuerias A, Herdeiro MT. Understanding physician antibiotic prescribing behaviour: a systematic review of qualitative studies. *International Journal of Antimicrobial Agents*. 2013;**41**:203–12.
- 37 Brookes-Howell L, Hood K, Cooper L, Little P, Verheij T, Coenen S, et al. Understanding variation in primary medical care: a nine-country qualitative study of clinicians' accounts of the non-clinical factors that shape antibiotic prescribing decisions for lower respiratory tract infection. *British Medical Journal Open*. 2012;**2**(4):e000796.
- 38 Jones MI, Greenfield SM, Bradley CP. Prescribing new drugs: qualitative study of influences on consultants and general practitioners. *British Medical Journal*. 2001;**323**(7309):378–81.

- 39 Flodgren G, Parmelli E, Doumit G, Gattellari M, O'Brien MA, Grimshaw J, Eccles MP. Local opinion leaders: effects on professional practice and health care outcomes. *Cochrane Database of Systematic Reviews*. 2011;**8**:CD000125.
- 40 de Bakker DH, Coffie DS, Heerdink ER, van Dijk L, Groenewegen PP. Determinants of the range of drugs prescribed in general practice: a cross-sectional analysis. *BMC Health Services Research*. 2007;**7**:132.
- 41 PEW Charitable Trusts. Persuading the Prescribers: Pharmaceutical Industry Marketing and its Influence on Physicians and Patients. Available from: <http://www.pewhealth.org/other-resource/persuading-the-prescribers-pharmaceutical-industry-marketing-and-its-influence-on-physicians-and-patients-85899439814> (last accessed 18 November 2015).
- 42 Spurling GK, Mansfield PR, Montgomery BD, Lexchin J, Doust J, Othman N, Vitry AI. Information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing: a systematic review. *PLoS Medicine*. 2010;**7**(10):e1000352.
- 43 Norris P, Herxheimer A, Lexchin J, Mansfield P. Drug Promotion: What We Know, What We Have Yet To Learn. Reviews of Materials in the WHO/HAI Database on Drug Promotion. Available from: <http://apps.who.int/medicinedocs/pdf/s8109e/s8109e.pdf> (last accessed 18 November 2015).
- 44 Khakhkhar T, Mehta M, Shah R, Sharma D. Evaluation of drug promotional literatures using WHO guidelines. *Journal of Pharmaceutical Negative Results*. 2013;**4**:33–8.
- 45 Ethical Standards in Health & Life Sciences Group. Guidance on Collaboration between Healthcare Professionals and the Pharmaceutical Industry. Available from: <https://www.rcpsych.ac.uk/pdf/Guidance%20on%20collaboration%20between%20healthcare%20professionals%20and%20the%20pharmaceutical%20industry.pdf> (last accessed 18 November 2015).
- 46 Greenhalgh T. No such thing as a free lunch. *British Journal of General Practice*. 2012;**62**(604):594.
- 47 World Health Organization, Health Action International. Understanding and Responding to Pharmaceutical Promotion: A Practical Guide. Available from: [http://www.researchgate.net/publication/264893905\\_Understanding\\_and\\_Responding\\_to\\_Pharmaceutical\\_Promotion\\_A\\_practical\\_guide](http://www.researchgate.net/publication/264893905_Understanding_and_Responding_to_Pharmaceutical_Promotion_A_practical_guide) (last accessed 18 November 2015).
- 48 Adamski J, Godman B, Ofierska-Sujkowska G, Osińska B, Herholz H, Wendykowska K, et al. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. *BMC Health Services Research*. 2010;**10**:153.
- 49 Australian Government Pharmaceutical Benefits Scheme website: [www.pbs.gov.au](http://www.pbs.gov.au).
- 50 Commonwealth Department of Health and Aged Care, 1998–2001.
- 51 NPS Medicinewise website: [www.nps.org.au](http://www.nps.org.au).
- 52 Sabuncu E, David J, Bernède-Bauduin C, Pépin S, Leroy M, Boëlle PY, et al. Significant reduction of antibiotic use in the community after a nationwide campaign in France, 2002–2007. *PLoS Medicine*. 2009;**6**(6):e1000084.
- 53 Trap B, Hansen EH, Hogerzeil HV. Prescription habits of dispensing and non-dispensing doctors in Zimbabwe. *Health Policy and Planning*. 2002;**17**(3):288–95.
- 54 Kaiser B, Schmidt C. Does physician dispensing increase drug expenditure? Empirical evidence from Switzerland. *Health Economics*. 2014; doi: 10.1002/hec.3124.
- 55 World Health Organization. Using Indicators to Measure Country Pharmaceutical Situations: Fact Book on WHO Level I and Level II Monitoring Indicators. Available from: <http://www.who.int/medicines/publications/WHOTCM2006.2A.pdf> (last accessed 18 November 2015).
- 56 World Health Organization. Country Pharmaceutical Situations: Fact Book on WHO Level I Indicators. Available from: <http://apps.who.int/medicinedocs/en/d/Js16874e/> (last accessed 18 November 2015).
- 57 Holloway KA. Combating inappropriate use of medicines. *Expert Reviews in Clinical Pharmacology*. 2011;**4**(3):335–48.
- 58 World Health Organization. Medicines Use in Primary Care in Developing and Transitional Countries: Fact Book Summarizing Results from Studies Reported between 1990 and 2006. Available from: [http://www.who.int/medicines/publications/primary\\_care\\_8April09.pdf?ua=1](http://www.who.int/medicines/publications/primary_care_8April09.pdf?ua=1) (last accessed 18 November 2015).
- 59 World Health Organization. The World Medicines Situation 2011, 3rd edn. Rational Use of Medicines.

- Available from: [http://www.who.int/medicines/areas/policy/world\\_medicines\\_situation/en/index.html](http://www.who.int/medicines/areas/policy/world_medicines_situation/en/index.html) (last accessed 18 November 2015).
- 60** Holloway KA, Gautam BR, Harpham T, Taket A. Influence of user fees and patient demand on prescribers in rural Nepal. *Social Science and Medicine*. 2002;**54**(6):905–18.
- 61** World Health Organization. Country Pharmaceutical Profiles. Available from: [http://www.who.int/medicines/areas/coordination/coordination\\_assessment/en/](http://www.who.int/medicines/areas/coordination/coordination_assessment/en/) (last accessed 18 November 2015).
- 62** World Health Organization. Effective Management of Medicines: Report of the South-East Asia Regional Consultation, Bangkok, Thailand, 23–26 April 2013. Available from: [http://www.searo.who.int/entity/medicines/documents/reort\\_regional\\_consultation\\_effective\\_management\\_of\\_medicines/en/](http://www.searo.who.int/entity/medicines/documents/reort_regional_consultation_effective_management_of_medicines/en/) (last accessed 18 November 2015).